autologous cmv-specific ctl
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01205334)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous cmv-specific ctl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06909110 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2025 | Stanford University |
| NCT04364178 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2020 | University of Pittsburgh |
| NCT01205334 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2010 | Baylor University, Methodist Cancer Center, Houston, Texas |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1